Universe Pharmaceuticals Inc.
Universe Pharmaceuticals Inc. (UPC) Revenue
Annual & quarterly revenue history · segment & region breakdown
UPC · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsUniverse Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.04B, a decrease of 22.44% year-over-year from $0.02B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-09-30 | $0.02B | -$0.01B | -22.44% |
| 2024-09-30 | $0.02B | -$0.01B | -28.74% |
| 2023-09-30 | $0.03B | -$0.01B | -19.52% |
| 2022-09-30 | $0.04B | -$0.01B | -16.34% |
| 2021-09-30 | $0.05B | +$0.02B | +56.27% |
| 2020-09-30 | $0.03B | -$0.00B | -7.60% |
| 2019-09-30 | $0.03B | +$0.00B | +16.54% |
| 2018-09-30 | $0.03B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Universe Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Universe Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Universe Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
UPC revenue · 4 questionsUPC's trailing twelve-month (TTM) revenue is $0.04B. That is a decrease of 22.44% year-over-year from $0.02B in FY2025.
▸ Source: FMP · Universe Pharmaceuticals Inc. SEC filings · GAAP · Universe Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026